One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...

Vertex Pharmaceuticals Inc. reported third-quarter sales that beat analysts’ expectations as the biotech company’s mainstay ...

Return on Assets (ROA): Vertex's financial strength is reflected in its exceptional ROA, which exceeds industry averages.

KING OF PRUSSIA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

A downtrend has been apparent in Vertex (VERX) lately with too much selling pressure. The stock has declined 17.7% over the ...

Thinking about what to do with Vertex Pharmaceuticals stock? You are not alone. The biotech powerhouse has seen its shares ...

A former executive at Microsoft, McAfee and Cisco becomes the fourth CEO in Vertex's 47-year history.

Analysts expect Vertex Pharmaceuticals to report an earnings per share (EPS) of $4.35. Investors in Vertex Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of ...

Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...